| CONTACT: Richard R. Current,
Vice President & CFO ,
517/372-9200 |
Neogen
reports record third quarter, 25% increase in net income
LANSING, Mich., March 20, 2003 –
Neogen Corporation (Nasdaq: NEOG) announced today that net income
for the third quarter of its 2003 fiscal year, which ended Feb.
28, was 25% higher than the previous year’s third quarter.
Net income per share was $0.16 for
the third quarter as compared with $0.13 for the same period last
year. The quarter marked the 40th consecutive profitable quarter
from operations for the Company. Net income for the first nine months
was $0.55 per diluted share, as compared to $0.45 for the prior
year. Neogen’s quarterly net income increased to $1,030,000
from $826,000 in FY 2002. Year-to-date net income is up 24% to $3,506,000,
compared to the prior year’s first nine months of $2,833,000.
“Our third quarter completes
an unbroken string of 10 years of quarterly profits from operations,”
said James Herbert, Neogen’s president. “Our compound
annual growth in revenue over the past five years has been over
20%. Few companies in today’s business climate can match our
record.”
Neogen’s third quarter revenues
were $11,102,000 — the first time the Company’s third
quarter revenues have exceeded $10 million. Revenues were 15% greater
than last year’s comparable quarter of $9,655,000. Revenues
for the Company’s first nine months were $34,272,000 compared
to $30,085,000 in the prior year.
Neogen’s Food Safety Division
third quarter revenues were up 30% compared to the prior year, with
broad-based increases across many market segments. Sales of test
kits to detect mycotoxins in feed and food products increased 53%
as geographic regions of the United States experienced conditions
causing natural toxin contamination in corn and other grains. Sales
of tests to detect two of these toxins, aflatoxin and fumonisin,
were more than double prior year levels.
Sales of Neogen’s test kits
to detect food allergens, including peanut, egg and milk residues,
continued their substantial growth trend by increasing 34% in the
third quarter on a year-to-year comparison. Neogen’s tests
to detect dangerous food pathogens, including E. coli O157:H7, Listeria
and Salmonella, improved 16%, and sales of dehydrated culture media
jumped 26%.
“The world’s news is full
of reasons why sales of our Food Safety products should continue
their strong growth into the foreseeable future,” said Ed
Bradley, Neogen’s vice president of Food Safety and Marketing.
“On almost a daily basis, news of a food recall due to a food
allergen or foodborne pathogen points to a need to do more testing
to ensure the safety of our food supply. The continuing move toward
fewer but larger multinational food producers also works in our
favor. Large multinationals prefer to use one-stop vendors that
can provide all their testing needs—Neogen’s strength.”
With the onset of war in Iraq, existing
Neogen diagnostic products and diagnostic test production capability
could be used to help counter the threat of retaliatory bioterrorism.
“We hope that situation does not happen,” said Herbert.
“But if bioterrorism does threaten, Neogen is equipped to
provide diagnostic products necessary to ensure the safety of our
food system, as well as help protect our plant and animal industries.”
Overcoming a difficult quarter-to-quarter
comparison, sales of Neogen’s Animal Safety Division in the
third quarter matched sales of the prior year quarter. In the prior
year’s third quarter, Neogen filled the initial stocking order
of veterinary instruments for 330 Tractor Supply Company (TSC) retail
stores across the United States, as well as an initial TSC warehouse
reserve. The Company’s Animal Safety Division also continues
to be adversely affected by poor economic conditions in the animal
protein market, as lower prices have led to less spending on animal
health products. The animal protein market is traditionally cyclical
in nature, and is showing signs of recovery.
The Animal Safety Division posted
increases in several of its markets, including sales of diagnostics
tests to detect drug residues, life science products, and certain
veterinary product lines. Since its original deal with TSC that
included 330 stores, Neogen has added approximately 100 new TSC
locations when the retailer purchased certain assets of the defunct
Quality Farm & Fleet retail chain, 30 Canadian TSC locations,
and the 116-store Orscheln’s retail chain with locations throughout
the Midwest United States.
“We’re very proud of what
we were able to accomplish in the third quarter with our Animal
Safety Division,” said Lon Bohannon, Neogen’s chief
operating officer. “We knew well in advance that this quarter
would be a difficult comparison. We are very optimistic that the
third quarter bodes well for our prospects for future growth within
the division.”
After the close of its third quarter,
Neogen announced its acquisition of Adgen Ltd., a private company
based in Ayr, Scotland. Since its founding in 1994, Adgen has been
a major distributor of Neogen products in Europe, as well as a producer
and marketer of its own agricultural diagnostic testing products.
The acquisition provides Neogen better access to the European Union,
and allows the Company to better serve its network of customers
and distributors throughout the EU. Adding Adgen’s experienced
research and development team will be a strong asset to Neogen as
it works toward developing the next generation of food safety diagnostic
testing products, especially products tailored to meet certain unique
requirements in the European market.
Neogen’s new location in Scotland
adds to the Company’s international physical presence established
earlier with the opening of its location in Shanghai, China, in
April 2002. Establishment of the Chinese location helped contribute
to Neogen’s sales growth in the first nine months.
Neogen Corporation develops
and markets products dedicated to food and animal safety. The Company’s
Food Safety Division markets dehydrated culture media, and diagnostic
test kits to detect foodborne bacteria, natural toxins, genetic
modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen’s Animal Safety Division markets
a complete line of diagnostics, veterinary instruments, veterinary
pharmaceuticals and nutritional supplements.
NEOGEN
CORPORATION SUMMARIZED CONSOLIDATED OPERATING DATA
(in
thousands, except per share)
|
|
|
|
Nine
months ended Feb. 28
|
|
|
|
|
|
|
| Revenue |
Food
Safety |
$6,206 |
$4,760 |
$18,876 |
$14,998 |
Animal
Safety |
4,896 |
4,895 |
15,396 |
15,087 |
| Total
revenue |
11,102 |
9,655 |
34,272 |
30,085 |
| Cost of
sales |
5,361 |
5,038 |
16,006 |
14,903 |
Gross
margin |
5,741 |
4,617 |
18,266 |
15,182 |
| Other
expenses |
Sales
& marketing |
2,656 |
2,142 |
8,017 |
6,549 |
Administrative |
1,049 |
929 |
3,141 |
3,106 |
Research
& development |
621 |
438 |
2,118 |
1,491 |
| Total other
expenses |
4,326 |
3,509 |
13,276 |
11,146 |
| Operating
income |
1,415 |
1,108 |
4,990 |
4,036 |
| Other revenue |
115 |
122 |
364 |
362 |
| Income
before tax |
1,530 |
1,230 |
5,354 |
4,398 |
| Income
tax |
500 |
404 |
1,848 |
1,565 |
| Net
income |
$1,030 |
$826 |
$3,506 |
$2,833 |
Net
income
per share |
$0.16 |
$0.13 |
$0.55 |
$0.45 |
| Other
information: |
Shares
to calculate per share |
6,386 |
6,441 |
6,368 |
6,365 |
Depreciation
& amortization |
$320 |
$315 |
$945 |
$813 |
Interest
expense |
0 |
0 |
0 |
0 |
Gross
margin (% of sales) |
51.70% |
47.80% |
53.30% |
50.50% |
Operating
income (% of sales) |
12.70% |
11.50% |
14.60% |
13.40% |
Revenue
increase vs. FY 2002 |
15.00% |
|
13.90% |
|
| Net income
increase vs. FY 2002 |
24.70% |
|
23.80% |
|
| |
NEOGEN
CORPORATION SUMMARIZED
CONSOLIDATED BALANCE SHEET DATA
(in thousands) |
| |
|
|
|
|
| Assets
|
| Current
assets
|
Cash
& investments |
$8,279 |
$6,353 |
|
|
Accounts
receivable |
7,262 |
6,462 |
|
|
Inventory |
8,767 |
8,683 |
|
|
Other
current assets |
1,714 |
1,751 |
|
|
| Total current
assets |
26,022 |
23,249 |
|
|
| Property
& equipment |
4,343 |
3,741 |
|
|
| Goodwill
& other assets |
13,515 |
12,914 |
|
|
| Total
assets |
$43,880 |
$39,904 |
|
|
| |
|
|
|
|
| Liabilities
& Stockholders’ Equity |
| Current
liabilities |
| Accounts
payable |
$1,688 |
$2,329 |
|
| Other current
liabilities |
2,544 |
1,635 |
|
| Total current
liabilities |
4,232 |
3,964 |
|
| Other liabilities |
394 |
394 |
|
Stockholders’
equity—shares out 6,107 in ‘03 & 6,081
in ‘02 |
|
|
|
39,254 |
35,546 |
|
| Total liabilities
& stockholders’ equity |
$43,880 |
$39,904 |
|
Certain portions
of this news release that do not relate to historical financial
information constitute
forward-looking statements. These forward-looking statements are
subject to certain risks and
uncertainties. Actual future results and trends may differ materially
from historical results or
those expected depending on a variety of factors listed in Management’s
Discussion and
Analysis of Financial Condition and Results of Operations in the
Company’s most
recently filed Form 10-K.
|